Oxypine

Quick links to important sections

Oxypine

Method of action: Antiepileptic

Treatment option: Seizure, Partial Seizures

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxypine

What is Oxypine? Quick Facts

Property Description
Active Ingredient Oxcarbazepine
Form Oral tablet, extended-release tablet, oral suspension
Pharmacological Class Anticonvulsant (Antiepileptic Drug)
General Purpose Neural stabilization and management of abnormal electrical activity
Origin Synthetic structural derivative (Prodrug)

What Type of Medicine is Oxypine?

Oxypine is a prescription-only medication with the active ingredient Oxcarbazepine, officially classified as an Anticonvulsant. This substance belongs to the synthetic dibenzazepine anticonvulsant pharmacological class and functions as an Antiepileptic Drug (AED), intended to stabilize neurological function. Oxcarbazepine is a structural derivative of Carbamazepine. Its use as an antiepileptic is established by its role in managing excessive nerve signaling.

Oxcarbazepine Composition and Available Forms

The therapeutic action of the drug is primarily exerted through the 10-monohydroxy metabolite (MHD), which is why the parent compound, Oxcarbazepine, is defined as a prodrug. Upon oral administration, the drug is rapidly converted to this active MHD, the component responsible for the core anti-seizure effect. The medication is supplied as a single-ingredient product and is available in multiple oral dosage forms, including immediate-release tablets, extended-release tablets, and an oral suspension (liquid). The availability of the liquid form often positions the product for improved administration in pediatric patients who may have difficulty swallowing tablets.

What is the General Purpose of an Anticonvulsant?

The general purpose of Oxypine as an anticonvulsant is to provide neural stabilization by reducing excessive electrical signaling within the brain. Its fundamental mechanism involves producing a blockade of voltage-sensitive sodium channels on nerve cell membranes, which stabilizes the hyperexcited nerves and helps prevent them from firing repeatedly. This primary action serves to manage and prevent the abnormal electrical impulses characteristic of neurological overactivity, serving the overarching purpose of an antiseizure drug.

Regulatory References

  1. Anticonvulsant (StatPearls - NIH)
  2. Antiepileptic Drug (StatPearls - NIH)
  3. Oxcarbazepine (StatPearls - NIH)

What side effects are possible with Oxypine?

Oxypine (Oxcarbazepine) is associated with adverse reactions that are officially classified by their frequency and the physiological system affected, according to regulatory documents.

Frequency and System-Organ Classifications

The most common adverse reactions are primarily related to the Nervous System and are often more frequently observed at the start of treatment or during dose escalation. Reactions categorized as Very Common (affecting more than 1 in 10 patients) include dizziness, somnolence (drowsiness), headache, and fatigue. Common effects (up to 1 in 10 patients) include diplopia (double vision), ataxia (impaired coordination), nausea, and vomiting. Other documented common effects involve the Metabolism and Nutrition system, specifically hyponatremia (low sodium levels).


Serious Adverse Reactions and Safety Considerations

Regulatory agencies explicitly document several serious adverse reactions. These include potentially life-threatening severe dermatological reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as multi-organ hypersensitivity reactions. There is also a documented risk of suicidal ideation and behavior associated with all antiepileptic drugs.

Safety characteristics are noted for specific populations. For instance, older adults have a higher risk for developing clinically significant hyponatremia. The medication is not recommended for use in individuals with severe renal impairment due to the potential for metabolite accumulation. Furthermore, the use of Oxcarbazepine has a documented potential to decrease the efficacy of hormonal contraceptives.

Overdose and Emergency Response

Overdose and When to Seek Help

Oxypine overdose is officially documented as an acute state characterized by an exaggeration of its neurological effects, requiring immediate emergency response. Documented clinical manifestations of overdosage include profound somnolence, confusion, and motor disturbances such as ataxia, diplopia, and abnormal gait. Gastrointestinal effects like nausea and vomiting are also listed in official regulatory labeling.


Severe Outcomes and Emergency Action

Severe and life-threatening outcomes can result from acute intoxication. These documented consequences include significant CNS depression, which may progress to coma and respiratory depression. Cardiovascular findings such as hypotension (low blood pressure) and bradycardia (slow heart rate) are noted, alongside the specific laboratory finding of hyponatremia (low serum sodium). Regulators require that individuals seek immediate medical attention for any suspected overdose, and emergency services must be contacted if the person has collapsed, experienced a seizure, or is struggling to breathe.


Management and Monitoring

Management consists of supportive and symptomatic treatment, as it is officially stated that no specific antidote is known for Oxcarbazepine. Clinical procedures, such as the administration of activated charcoal or gastric lavage, may be considered. Close monitoring of the patient’s vital signs, neurological status, and laboratory values is warranted following acute exposure.

Therapeutic Uses of Oxypine

Controlling Focal Seizures and Neurological Instability

Oxypine is primarily utilized for the long-term management of epilepsy, focusing on conditions characterized by periods of heightened symptoms such as focal (partial) seizures. It is relevant for use in adults and is applied when appropriate for pediatric patients. The main therapeutic areas include monotherapy and adjunctive therapy for conditions presenting with disruptive symptom manifestations. The medication supports stabilizing neurological function and is applied in addressing these episodes. It contributes to easing the overall symptom load and is used for managing symptoms that interfere with daily functioning. This supports the patient during difficult episodes by easing distress.

“This medication is commonly used to help patients cope more steadily with symptom fluctuations associated with recurrent neurological activity.”


Relief for Severe Episodic Nerve Pain

Beyond epilepsy, Oxypine is commonly applied in the management of specific, intense pain syndromes, most notably trigeminal neuralgia. This condition is marked by recurrent, sudden-onset bouts of sharp shooting facial pain. The medication helps with easing the overall symptom load of these severe pain attacks and assists with reducing their occurrence. This use may be part of symptomatic management in clinical settings to provide support for patients experiencing this chronic and debilitating form of neuropathic pain.

Quick Fact: Relief for Episodic Pain Oxypine is relevant in conditions involving recurrent or episodic manifestations of severe pain and is applied when appropriate for managing symptoms that interfere with daily functioning.

Eligibility and Restrictions for Use

Eligibility for Oxypine: Official Regulatory Status

The eligibility for using Oxypine (Oxcarbazepine) is strictly defined by regulatory health authorities based on patient population, age, history of hypersensitivity, and specific organ function status.


Absolute Contraindications

The medicine is contraindicated in patients with a known history of hypersensitivity to oxcarbazepine or any of its components. This prohibition also extends to patients with known hypersensitivity to the related compound eslicarbazepine acetate.


Age-Related Eligibility

Population Status (Immediate Release Formulations)
Adults (17+ years) Approved for use as monotherapy and adjunctive therapy.
Children geq 4 years Approved for use as monotherapy.
Children geq 2 years Approved for use as adjunctive therapy.
Children < 2 years Use not established for adjunctive therapy.

Conditional Restrictions

Use is not recommended in patients with severe hepatic impairment because safety data in this population have not been established. Patients with severe renal impairment (creatinine clearance < 30 mL/min) require conditional use, starting therapy at a reduced initial dose. Furthermore, patients with specific genetic factors, such as the HLA-B*1502 allele, should avoid use unless the benefits outweigh the risks due to the increased chance of severe dermatological reactions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oxypine’s official interaction profile is defined by the activity of its metabolite, MHD, which modulates drug-metabolizing enzymes and creates specific co-administration constraints.


Pharmacokinetic Interactions and Exposure Modification

  • Enzyme Modulation: MHD is a documented inducer of CYP3A4/5, which reduces the plasma concentration and effectiveness of co-administered substrates, such as the components of hormonal contraceptives. MHD is also an inhibitor of CYP2C19, which causes increased plasma concentration of certain medicines, including Phenytoin.
  • Reduced Oxypine Exposure: Co-administration with enzyme-inducing anticonvulsants, Rifampin, or the herbal product St. John’s wort is officially documented to decrease MHD plasma levels.

Pharmacodynamic Effects and Restrictions

  • Additive CNS Effects: There is a documented pharmacodynamic interaction with alcohol and other CNS depressants that increases the risk of dizziness and somnolence.
  • Electrolyte Risk: An additive effect with diuretics and other sodium-lowering agents is documented, increasing the risk of hyponatremia (low sodium levels).
  • Administration Timing: The extended-release tablet requires an official timing restriction, mandating it be taken on an empty stomach (one hour before or two hours after a meal).
  • Renal Constraint: In patients with severe renal impairment (CrCl < 30 mL/min), the systemic exposure (AUC) of the active metabolite is officially documented to be approximately two-fold higher.

Mechanism of Action

How Oxypine Works

Oxypine acts as a prodrug, which is rapidly converted to its primary active agent, the 10-monohydroxy derivative (MHD), in the body. MHD's mechanism is centered on neuronal voltage-gated sodium channels ( Na v). MHD binds preferentially to the inactive state of these channels, preventing the necessary Na^+ ion influx required to propagate an electrical signal. This action is use-dependent, meaning it selectively blocks channels in neurons firing at high frequencies, which results in the attenuation of high-frequency neuronal discharges.

Secondary mechanistic modulation involves voltage-gated calcium channels ( Ca v). By influencing these channels, the drug indirectly limits the release of excitatory chemical messengers from the presynaptic terminal. This complementary action further suppresses the propagation of abnormal signals throughout neural pathways, contributing to the modulation of neural circuit activity. The rate of prodrug biotransformation influences the pharmacodynamic expression of the channel blockade.

Dosage and Administration Information

Oxypine (Oxcarbazepine) is administered strictly via the oral route, available as immediate-release tablets, extended-release tablets, and an oral suspension. The specific formulation dictates the required frequency and administration conditions.

The medicine's use begins with a gradual dose titration. The typical adult initial dose is 600 mg per day, often taken in two divided doses when using the immediate-release form. The dose is then increased slowly, generally at approximately weekly intervals, to reach a target maintenance range, which commonly falls between 1200 mg and 2400 mg daily. This gradual increase is a procedural requirement of the overall usage protocol.

Immediate-release forms are typically taken twice a day, while the extended-release tablet is administered once a day. A critical distinction is the timing relative to meals: the extended-release tablet must be taken on an empty stomach, whereas the immediate-release forms can be taken independently of food. The oral suspension requires the bottle to be shaken before measuring.

Specialized instructions exist for certain populations. For adults with severe renal impairment (creatinine clearance < 30 mL/min), the starting dose is reduced by 50% to 300 mg per day, and subsequent titration must proceed slowly. In pediatric patients (ages 4 to 16), the starting dose is calculated based on the individual's body weight. Furthermore, the extended-release tablets must always be swallowed whole and should not be crushed or chewed, a procedural constraint tied to the drug’s intended release profile.

Recent Clinical Evidence

Oxypine: Research Evidence Overview

Evidence for use in Partial-Onset Seizures (Focal Seizures)

Research examining Oxypine has studied it for conditions characterized by fluctuating or episodic manifestations, specifically Partial-Onset Seizures. Studies explored its evaluation both when used alone (monotherapy) and when added to an existing seizure treatment (adjunctive therapy). These research efforts included short-term, double-blind placebo-controlled trials and Randomized Controlled Trials (RCTs) where participants were observed over defined time intervals.

Primary outcomes that research examined included measures of daily functioning or activity level, such as the median percentage change in seizure frequency measured over a set period and the proportion of participants who experienced a certain level of change as measured in seizure activity. Findings describe patterns observed in the studies related to the measured changes in seizure frequency. However, results apply only to the populations studied and reflect the specific conditions under which the research was conducted.

Long-Term Studies and Follow-Up Data

Research explored short-term symptom changes, with most controlled clinical trials observing participants for durations lasting less than 26 weeks. While open-label extension studies research provides insight into short-term changes that were sustained for a few months, there is limited information for long-term outcomes. Long-term effects are not fully established. Therefore, data for long-term use, especially regarding the durability of any observed patterns, remain insufficient, and research is ongoing.

Evidence in Special Populations

Oxypine was evaluated in different age groups. Studies observed outcomes related to episodic or acute changes in adult patients, as well as several groups of pediatric patients, including children aged 4 to 16 years. However, data for certain groups remain insufficient. For instance, there is limited information available from formal studies for very young children or patients with severe kidney problems, and long-term effects are not fully established for these populations.

Interpreting the Research: What Remains Uncertain

Research provides context but has several limitations. Follow-up durations were limited in the high-certainty RCTs, meaning the understanding of long-term effects are not fully established. Evidence quality varies across studies, with systematic reviews sometimes noting low certainty for specific findings. Furthermore, comparative evidence is lacking in some areas, making it challenging to understand how patterns of use compare to other treatments where comparative evidence is lacking.

Key Studies & References

  1. Epilepsies in children, young people and adults - NICE Guideline NG217

Frequently Asked Questions (FAQ)

Common questions about Oxypine (FAQ)


Q: How long does the effect of a single dose of Oxypine last in the body?

According to official drug labeling, the active component of Oxypine, known as MHD, is primarily responsible for the therapeutic effect. In adults, this active component has an elimination half-life of approximately nine hours. This measure indicates the time it takes for the body to process and remove half of the substance.


Q: What is the connection between Oxypine and changes in metabolism or weight?

Official information indicates that Oxypine is associated with weight gain in some clinical trials, which was reported by a small percentage of patients, particularly those on higher doses. Furthermore, the drug is commonly linked to changes in the body's electrolyte balance, specifically the risk of hyponatremia (low sodium levels). This is a finding that warrants professional consideration.


Q: What does official information say about Oxypine causing anxiety or restlessness?

Anxiety and restlessness, sometimes described as feeling agitated or hyperactive, are reported side effects listed in official drug information. These may be signs of the medication's effect on mood and behavior. If these feelings are persistent or cause concern, official guidance recommends consulting with a healthcare professional.


Q: Does Oxypine interact with common over-the-counter pain relievers or cold medicines?

Official regulatory guidance advises general caution before combining Oxypine with any other products. This includes prescription and over-the-counter medicines, vitamins, or herbal products. Many drugs have the potential to alter the concentration of Oxypine's active metabolite in the blood, so consulting with a healthcare professional before co-administration is consistent with regulatory recommendations.


Q: Can taking Oxypine affect a person's ability to drive or operate machinery?

Yes, Oxypine can cause side effects like dizziness and drowsiness. Official warnings state that activities requiring mental alertness, such as driving or operating machinery, should be avoided until an individual knows how the medicine affects them.


Q: Is it common for people to report dry mouth or constipation while taking Oxypine?

Yes, regulatory documents list both dry mouth and constipation among the possible side effects associated with Oxypine. These effects are generally reported less frequently than the most common side effects.


Q: How quickly do most patients start to notice the intended effects of Oxypine?

The drug's active component reaches stable levels in the bloodstream within approximately two to three days when the medicine is taken twice daily. However, the full therapeutic benefit is generally linked to the period of gradual dose titration, which occurs over several weeks.


Q: What is the typical time frame for the full therapeutic benefit of Oxypine to be seen?

The full therapeutic benefit is generally achieved after the initial period of gradual dose titration is complete. Official dosing instructions describe increasing the dose slowly, a process that can take approximately two to four weeks to reach the target maintenance range.


Q: If Oxypine is stopped, how long does it take for the substance to clear out of the system?

The active metabolite (MHD) has a half-life of approximately nine hours in adults. The medicine is primarily cleared from the body through the kidneys. More than 95% of the dose eventually appears in the urine as metabolites.


Q: Is it normal to feel a change in symptoms after only a few days of starting Oxypine?

Yes, the active metabolite reaches stable plasma concentrations in as little as two to three days after starting the drug. This means both the intended actions and any potential side effects may begin to occur early during the initial adjustment period.


Q: Is there a high rate of discontinuation when people first start taking Oxypine?

Clinical trial data indicate that higher doses of the medication, doses above the recommended daily range, were generally not tolerated by patients due to central nervous system effects. This resulted in higher discontinuation rates at those upper dose levels.


Q: What is the most commonly reported side effect that users experience with Oxypine?

The official product information classifies several adverse reactions as Very Common, meaning they affect more than 1 in 10 patients. These most frequently reported effects include dizziness, somnolence (drowsiness), headache, and fatigue.


Q: Do the side effects of Oxypine usually lessen or go away after a few weeks?

The labeling indicates that some side effects are generally temporary. The most common adverse reactions are often more frequently observed at the start of treatment or during the period when the dose is being increased. If any side effect becomes severe or concerning, it should be discussed with a healthcare professional.


Q: Are there any long-term physical side effects associated with continuous Oxypine use?

The current understanding of long-term effects is not fully established. Most high-certainty clinical trials observed participants for durations lasting less than six months. For this reason, data concerning the long-term use of Oxypine remains officially insufficient.


Q: Does Oxypine commonly cause drowsiness or fatigue in users?

Yes, somnolence (drowsiness) and fatigue are both listed among the most frequently reported adverse reactions. They are classified as Very Common, meaning they are expected to affect a significant number of patients.


Q: Are changes in sleep patterns (like insomnia or increased sleep) a known effect of Oxypine?

The most common effect on sleep is somnolence (drowsiness). Official adverse reaction lists also include trouble sleeping (insomnia) as a potential, though less common, side effect of the medication.


Q: Is there a risk of physical dependence or addiction described for Oxypine?

Official drug labeling includes dedicated sections for Drug Abuse and Dependence. However, Oxypine is not classified as a controlled substance by regulatory bodies, and no established risk of addiction is specifically listed.


Q: What research is available on Oxypine's effect on cognitive function or memory?

Regulatory documents list various cognitive symptoms as potential adverse reactions. These include difficulties with concentration, psychomotor slowing, and speech or language problems. These cognitive effects were reported more often in patients receiving the medication than in those taking a placebo.


Q: Does Oxypine have a known risk of causing changes in body temperature regulation?

While not listed as a common side effect, a small, non-clinically significant negative shift in body temperature was noted in some patients during a review of vital sign data from clinical trials. This finding may relate to the drug's effect on thyroid hormones.


Q: What precautions are advised for people taking Oxypine during hot weather?

Official warnings state that precautions are advised to avoid overheating or dehydration. This includes avoiding strenuous exercise or exposure to hot weather, and ensuring adequate fluid intake, due to the risk of certain side effects.


Q: Is Oxypine safe for use during pregnancy, according to authoritative sources?

Official labeling indicates that Oxypine may cause harm to a fetus. Official guidance notes that the provider must weigh the potential benefits against the possible risk of harm to the fetus. The use of Oxypine during pregnancy requires careful monitoring by a healthcare professional.


Q: What is known about the risks of Oxypine being used while breastfeeding?

Official summaries from regulatory bodies indicate that the drug’s active metabolite is present in breast milk, though usually at low levels. Official guidance suggests that the infant may be monitored for effects such as drowsiness and adequate weight gain, especially in younger or exclusively breastfed infants.

How should Oxypine be stored and disposed of?

Oxcarbazepine (Oxypine) must be stored and disposed of according to official regulatory requirements to maintain stability and prevent unintentional exposure.

Storage Requirements

Condition Official Specification
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Excursions up to 30 C (86 F) are permitted.
Handling Keep the container tightly closed and protect from excess heat and moisture; avoid freezing.
Child Safety Store all medication out of the sight and reach of children.
Stability The oral suspension must be discarded 7 weeks after the bottle is first opened.

Disposal Requirements

Expired or unused Oxcarbazepine should not be flushed down the toilet unless explicitly authorized by the regulator. It should be disposed of in the household trash after being mixed with an undesirable substance (e.g., dirt) in a sealed container, following local pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxypine found in:

A-Z Index: